L. plantarum 299v.
Bloating fighter. Settles everyday digestion: less gas, less bloating, more predictable bowel habits. It also helps your body take up more iron from a plant-based meal.
Reviewed March 2026
- Category
- Probiotic
- Also filed under
- IBSBloatingIron
What L. plantarum 299v is, and what it does.
- Does it work
- Suits people whose digestion reacts to most meals, and anyone getting their iron mainly from plants. The label has to name 299v, not just the species.
- How much to take
- No dose figure is on record for this strain. Labels count live cells per serving, and 299v has to be named on the label for the research to apply.
- Time to feel it
- Digestive changes usually land somewhere in weeks two to four of daily use. The iron effect shows up on a blood panel rather than in how you feel.
- The first dose
- Day one is quiet. A bit of extra wind is common while the gut adjusts, and it settles within a few days.
- With regular use
- Digestion tends to settle across weeks two to four and holds while intake continues. The iron work reads on a blood panel over a longer stretch.
- How well tolerated
- Well tolerated across human studies. Mild gas early on is the usual report. People under medical care should check with their doctor before starting a live culture.
- How it feels
- Mostly the absence of something: less rumbling, fewer surprises after eating. A gut that stops interrupting rather than a sensation you notice.
- The overlooked benefit
- Its lactic acid keeps iron in the soluble ferrous form, which is why this strain was studied for iron uptake and not only for digestion.
1,000,000,000 to 10,000,000,000 CFU a day is where L. plantarum 299v works.
Source: ISAPP consensus statement 2019 + Ford 2014 meta-analysis
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 25 human trials.
- digestive comfort and occasional bloatingMeta-analysis
- iron absorption from a mealRandomised trial
- microbiome balanceRandomised trial
- gut barrier integrityIn vitro study
Questions people ask about L. plantarum 299v.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- How long until I notice something?
- GI effects can show within days. Immune and mood benefits take 4-8 weeks of consistent use.
- Do I need to refrigerate it?
- Depends on the brand. Shelf-stable formulas exist and work fine. But if it says refrigerate, do it. Dead bacteria don't help anyone.
- Should I take it with food?
- With or right before a meal, ideally. The food buffers stomach acid and gives the bacteria a better chance of surviving the trip down.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Who benefits most from this?
- People with a specific, evidence-backed need. Lactobacillus Plantarum 299v has strong research. If your situation matches the studied use case, it's one of the more reliable supplements you can take.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
This strain is well known for raising non-heme iron uptake, with organic acids from fermentation keeping iron in the more soluble ferrous state at the absorptive surface. It is one of the few strain-level absorption effects described in the literature.
Ascorbate reduces ferric to ferrous iron and holds it soluble in the duodenum, the same chemistry the strain's lactate contributes to. The two reach the same absorption step from different angles.
Plantarum species ferment chicory fructans readily, so inulin supplies the carbon source the delivered strain uses to establish. Substrate plus strain is the standard synbiotic construction.
Short fructans are fermented early in the colon by lactic acid bacteria, giving the strain usable substrate soon after transit. The acidification that follows favours lactobacilli over acid-sensitive genera.
Partially hydrolysed guar ferments gradually and further down the colon, extending the substrate window past the short fructans. Its low gas profile is why it appears in strain formulas aimed at sensitive digestion.
Lactate and acetate released by plantarum are consumed by bifidobacteria and butyrate producers, so the genera feed one another metabolically. Multi-genus blends rest on this cross-feeding.
A yeast does not compete with lactobacilli for the same carbon sources or adhesion sites and tolerates the acidic environment they create. Long-standing practice pairs the two in one formula for that reason.
Charcoal binds luminal organic material indiscriminately, including the substrates and metabolites the strain relies on. Separate the two by several hours rather than dosing together.
Berberine has direct antibacterial activity and measurably shifts gut community composition, which includes lactic acid bacteria delivered at the same time. Spacing the doses preserves viable counts.
Carvacrol and thymol disrupt bacterial membranes without selecting between residents and a delivered strain. Concurrent dosing lowers the viable count that reaches the colon.
Work in adults starting oral iron reports better gastrointestinal tolerance and improved iron status markers when a probiotic is taken alongside; L. plantarum 299v is the strain most often named in this line of work. The proposed route is lactate production lowering local pH and keeping iron in the more absorbable ferrous state. Status markers are markers, and the strain-specific size of the effect is not settled.
Lactate lowers luminal pH, and calcium solubility rises as pH falls, which is the same chemistry behind fermented dairy calcium availability. In vitro fermentation models report increased soluble mineral fractions. Nothing here has been measured as a change in calcium status in people taking this strain.
Magnesium absorption also depends on the mineral staying soluble in the intestinal lumen, and organic-acid-producing bacteria shift that equilibrium. The reasoning follows the same in vitro fermentation observations used for zinc and calcium. It has not been tested as a human magnesium outcome.
Cultured Lactiplantibacillus plantarum strains take up inorganic selenium and incorporate it into organic selenium species during growth, which is the basis of selenium-enriched probiotic ingredients. That is a manufacturing observation in culture, not something that happens usefully in the gut from a co-taken tablet. Distinguish the enriched ingredient from the plain strain plus a selenium capsule.
Resistant starch reaches the colon undigested and is fermented by resident and supplemented bacteria to short-chain fatty acids, butyrate prominent among them. L. plantarum contributes to the cross-feeding chain rather than producing butyrate itself. The measurable output is a fermentation product, not a clinical endpoint.
Psyllium is only partly fermented, so it adds bulk and viscosity while still feeding some fermentation. Combining it with a lactobacillus gives both a physical and a microbial route to stool consistency. Take psyllium with enough water and expect it to slow the transit of anything taken with it.
Pectin is fermented in the proximal colon and supports acid production by lactic acid bacteria. It also binds some minerals in transit, which is worth noting in a mineral-containing formula. The pairing rationale is substrate supply, not a studied combination.
Oat beta-glucan is viscous and fermentable, giving lactic acid bacteria substrate lower down the tract. The viscosity itself slows gastric emptying, which changes the delivery timing of anything co-taken. No combination trial with this strain exists.
Lactobacilli and bifidobacteria occupy different colonic niches and cross-feed on each other's fermentation products. Multi-strain blends are standard formulation practice for that reason. Evidence generated for a single strain does not transfer to a blend containing it, and a label should not imply it does.
Both are acid-tolerant lactic acid bacteria used together in commercial blends, with overlapping rather than identical substrate preferences. Combining them raises total colony count without changing the mechanism. Strain-specific claims stay with their own strain.
Glutamine is the preferred fuel of small intestinal enterocytes, while short-chain fatty acids from bacterial fermentation feed colonocytes. The two supply different parts of the same barrier from different directions. That is mechanistic complementarity, not a demonstrated combined effect.
Lactate produced by L. plantarum is a substrate for butyrate-producing bacteria through established cross-feeding, so the strain sits upstream of butyrate rather than making it. Supplemental butyrate supplies the end product directly. Understanding which end of the chain a product occupies avoids double-counting the same mechanism.
Lactoferrin binds iron tightly and is reported to favour lactobacilli and bifidobacteria over iron-scavenging competitors in culture. Pairing it with a lactobacillus is a plausible combination on that basis. The supporting work sits in culture and infant-feeding studies rather than in adults taking this strain.
Bovine colostrum carries oligosaccharides that are fermentable and immunoglobulins that act in the lumen. Formulators pair it with probiotics on that dual rationale. The combination itself is untested and colostrum is a dairy-derived material to declare for allergen reasons.
Catechins show antibacterial activity in culture against a range of organisms including lactic acid bacteria. Co-formulating a concentrated catechin extract in the same capsule as live cells is a viability risk worth testing rather than assuming. This is an in vitro observation, and the in-use significance depends on the formulation.
Some lactic acid bacteria consume or produce B-group vitamins during fermentation, and B12 handling differs sharply between species and strains. L. plantarum is generally not a meaningful B12 producer for the host, since colonic synthesis is distal to the absorption site. Do not let a probiotic label imply a B12 contribution.
Several Lactiplantibacillus plantarum strains synthesise folate during fermentation, which is why the species is used in folate-biofortified foods. Whether colonic synthesis reaches host circulation in a useful amount is a separate and unsettled question. Strain matters and the claim belongs to the strain that was assayed.
Nothing specific on file for L. plantarum 299v. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What L. plantarum 299v actually does.
Lactiplantibacillus plantarum is a facultatively heterofermentative lactic acid bacterium that ferments a wide range of carbohydrates to lactate, and that acid output is what lowers luminal pH in its immediate environment.
Lowering luminal pH keeps iron in the ferrous state and raises the soluble fraction of divalent minerals, which is the recognised chemical link between lactic acid fermentation and mineral availability.
Probiotic effects are strain-specific by definition. Evidence generated with the 299v strain does not transfer to other Lactiplantibacillus plantarum strains, and a label that names only the species is not describing the same organism the trials used.
Colony forming units are a count of viable cells at the time of testing, and viability declines with heat and moisture over shelf life, which is why an at-manufacture count and an end-of-shelf-life count are different numbers.
Where L. plantarum 299v comes from.
It is grown, not extracted. A stored sample of this exact strain is fed in a tank, the cells are separated from the liquid, mixed with sugars that help them survive freezing, then frozen and dried into a powder. Each batch is counted on a plate to work out how many living cells are in it, and that count is what ends up on the label.
Built by fermentation, the same way vitamin B12 and many amino acids are made at scale. Controlled conditions, consistent output.
A characterised deposit of the 299v strain held as a master and working cell bank, with identity confirmed genetically rather than by phenotype.
Cells are grown in a controlled fermenter on a carbohydrate and nitrogen medium with pH held by base addition, because the organism acidifies its own broth as it grows.
Biomass is separated from spent medium by centrifugation or membrane filtration and washed to remove residual medium components.
Sugars and other cryoprotectants are added before drying, because the freezing and drying steps are what kill most cells if unprotected.
The concentrate is frozen and dried under vacuum to a low-moisture powder. Residual moisture is the single biggest determinant of how fast viability falls afterwards.
Plate counts set the potency of each lot, and lots are blended with carrier to a declared CFU per serving, usually with an overage to cover shelf-life loss.
Filled into capsules, delayed-release shells, sachets, or inoculated into a food base for a live-culture drink.
Getting L. plantarum 299v from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In women of reproductive age, probiotic and prebiotic supplementation was associated with better iron absorption and modestly higher haemoglobin levels.Systematic review. Apte et al., 2025 (BMC nutrition). PMID 39920867 ↗
- Pooled trials reported modestly lower circulating cortisol with probiotic supplementation, with the certainty of the pooled estimate graded as limited.Meta-analysis. Gandomkar et al., 2026 (BMC nutrition). PMID 42032711 ↗
- In runners, a probiotic taken around racing was compared with placebo for markers of gut, muscle and kidney stress, and race distance rather than the supplement explained most of the marker changes.Randomised trial. Hansson et al., 2026 (Journal of the International Society of Sports Nutrition). PMID 41981959 ↗
- In a double-blind randomised design, supplementation with the 299v strain was associated with shifts in plasma metabolite profiles relative to placebo; these are biochemical markers, not clinical endpoints.Randomised trial. Godzien J et al., 2025 (Journal of Affective Disorders). PMID 39271063 ↗
- A feasibility study reporting that the 299v supplementation protocol could be delivered and adhered to in an urban academic clinical setting; feasibility studies are designed to test logistics, not effect.Open-label trial. OjiNjideka Hemphill N et al., 2023 (Nutrients). PMID 36839232 ↗
- Lactiplantibacillus plantarum strains accumulated inorganic selenium from the growth medium and incorporated part of it into organic selenium species, which the authors frame as a biotechnological route to selenium-enriched cultures.In vitro study. Szafranska J et al., 2025 (International Journal for Vitamin and Nutrition Research). PMID 41201224 ↗
- In animals exposed to chronic stress, Lactiplantibacillus plantarum intake was associated with less gastrointestinal tissue damage than in unsupplemented animals; an animal finding, and not human evidence.Animal study. Castro-Rodriguez DC et al., 2025 (ACS Omega). PMID 41280824 ↗
- A systematic review of randomised controlled trials that catalogues the probiotic strains studied for mood-related endpoints, naming L. plantarum 299v among them, and concludes the trial base remains limited and heterogeneous.Systematic review. Johnson D et al., 2026 (Journal of Psychopharmacology). PMID 41453849 ↗
- A systematic review of psychobiotic strains, their metabolites and study designs that names L. plantarum among the organisms reviewed; the review summarises the literature rather than reporting a new result.Systematic review. Sliwka A et al., 2025 (Nutrients). PMID 40647242 ↗
- Screening across in vitro fermentation and cell models identified probiotic strains that increased the soluble and cell-associated fraction of dietary minerals; a model-system result, not a measure of human mineral status.In vitro study. Liu B et al., 2025 (Frontiers in Microbiology). PMID 41834858 ↗
- A non-human model reported greater zinc transport when a Bifidobacterium strain was given with zinc sulfate than with zinc alone, which the authors describe as a synergistic effect on zinc handling.Animal study. Wang H et al., 2026 (Frontiers in Nutrition). PMID 42293195 ↗
These are the studies our verdict leans on, chosen from the 555 we read for L. plantarum 299v. The full linked list is below.
The studies, linked.
3 sources behind our L. plantarum 299v verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialProbiotics for Reduction of Pathogenic Bacteria in Connection With Advanced Surgery in the Mouth, the Oropharynx, and on the NeckClinicalTrials.gov ↗NA · 45 participants · Completed
- Clinical trialProbiotics for Reduction of Colonisation With Clostridium Difficile in Antibiotic Treated Intensive Care PatientsClinicalTrials.gov ↗NA · 25 participants · Terminated
- Clinical trialRandomized Double Blind Placebo Controlled Trial on a Probiotic Mixture (L. Rhamnosus GG Plus L. Plantarum 299V) in Pediatric Irritable Bowel Syndrome: Clinical Efficacy and Multiomics ApproachClinicalTrials.gov ↗NA · 124 participants · Not yet recruiting
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.